Breaking AI & Tech News Analyzed

The Breakthrough in Breast Cancer TreatmentA landmark international study has revealed that millions of women with breast cancer could safely skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn't. The randomised trial specifically examined whether the test could identify patients who would not benefit from chemotherapy, allowing them to avoid the potentially debilitating treatment without compromising their outcomes.The Scientific Evidence Behind the TestThe results of the Optima trial, which will be presented at the American Society of Clinical Oncology's annual meeting, are being hailed by experts as gamechanging. The five-year cancer-free survival rate was 93.7% in the group that skipped chemotherapy, which was statistically non-inferior to the 94.9% rate in patients randomly assigned to receive chemotherapy.The Prosigna genomic test analyzes the activity of 50 specific genes in tumor tissue to determine the molecular subtype and develops a risk of recurrence score to help doctors decide if chemotherapy is necessary. This precision medicine approach allows for personalized treatment decisions based on the unique characteristics of each patient's cancer.A Patient's Journey to Avoiding ChemotherapyKaren Bonham, a speech and language therapist from Swansea in Wales, was one of 4,429 patients with breast cancer recruited to the trial from countries including the UK, Norway, Sweden, Australia, New Zealand and Thailand. Diagnosed with cancer in 2017 at the age of 55 after routine breast screening, Bonham described the news as shocking."It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive," she said. Dreading chemotherapy, she agreed to join the Optima trial after undergoing surgery. She was only days away from starting treatment and had already cut her hair short when the results came back in September 2017.While taking a walk on a Welsh beach, Bonham received a phone call from her hospital informing her she had been allocated to the group of patients that would not be having chemotherapy. "How to describe the initial feeling? Immense relief? Like Christmas? Certainly a mixture of the two," she said.The Future of Personalized Cancer CareToday, Bonham, now 64, retired and living in Cardiff, is free of cancer, healthy and shows no signs of the disease coming back. "It is coming up to nine years since my diagnosis," she said. "I am mindful of my diagnosis, alert to potential changes in my body but do not feel defined by [it]. I walk, enjoy yoga and live well."While not every woman with breast cancer will be able to skip chemotherapy—the treatment remains necessary and important for many—the trial results suggest that genomic testing can safely identify those who can avoid it. This approach represents a significant shift toward personalized medicine in oncology, reducing unnecessary treatment and its associated side effects while maintaining excellent outcomes."I hope that the trial will bring positive patient outcomes to many," Bonham said, reflecting on the potential impact of this research on future breast cancer patients.

The LeadRobert Smith, a distinguished pharmacologist and professor at St Mary's medical school in London (now part of Imperial College), has died aged 92. His groundbreaking work on how genetic variations affect drug responses helped shape the field of personalized medicine.The Discovery of Debrisoquine PolymorphismBob became well known for his role in the discovery of "debrisoquine polymorphism." In 1975, as one of five volunteer researchers who took debrisoquine, a blood pressure medication, he was the only one to suffer adverse effects (hypotension) and collapse. This led to the discovery of a genetic polymorphism where certain individuals cannot break down specific drugs efficiently. While Bob described this as an "accident waiting to happen," it positioned him at the forefront of pharmacogenetics.Awards and RecognitionSmith's contributions to pharmacology were formally recognized when he became the first recipient of the Paton prize in 1998 for his work in understanding how genes affect drug response. His academic achievements included becoming professor of pharmacology in 1978 and serving as deputy dean of the medical school from 1980-88.Impact on Medicine and SportsSmith's research fundamentally changed how medical professionals understand drug responses, paving the way for personalized medicine approaches. Beyond human medicine, he applied these principles to horse racing, chairing the UK Horserace Scientific Advisory Committee (1979-99) and its pan-European equivalent (1992-2005). He also served as a director of the Horseracing Forensic Laboratory in Newmarket during the 1990s, helping shape anti-doping protocols.Enduring LegacySmith never fully retired, continuing his research as emeritus professor until publishing his last paper in 2020. His legacy extends beyond scientific contributions to include the principles, warmth, kindness and generosity he embodied throughout his career. His work continues to influence pharmacology and personalized medicine, ensuring his impact will be felt for generations to come.